Kymera Therapeutics outlined progress in its oral pipeline at the Wells Fargo 21st Annual Healthcare Conference, highlighting accelerated timelines for Phase 2b studies in moderate to severe atopic dermatitis and type 2 asthma. The biotech, founded about 10 years ago, reported revenue of $105 million over the last twelve months, marking a 135% year-over-year growth driven primarily by collaboration agreements. Its stock has seen a 50% year-to-date return, reflecting investor confidence in its innovation-driven strategy, though volatility remains elevated with a beta of 1.96. The company aims to build a commercial biopharma company focused on delivering oral therapies that match or exceed the efficacy of injectable biologics like dupilumab, a standard treatment for type 2 inflammatory diseases.
Kymera’s lead candidate, KT-621—a first-in-class oral STAT6 degrader—is designed to block IL-4 and IL-13 signaling pathways, with Phase 1b studies involving around 200 subjects. The company has completed all necessary toxicology studies to initiate Phase 3, and its Phase 2b BROADEN2 trial in atopic dermatitis has been updated to a readout by the end of 2026, up from a prior mid-2027 target. The study includes a 52-week open-label extension and tests three dose levels, with the middle dose expected to achieve maximal pharmacology. Baseline disease severity is measured via EASI scores, which have shifted from the low 30s to mid-20s.
KT-579, an IRF5 degrader, is also advancing toward regulatory milestones. Phase 1 data are anticipated before the end of 2026, with a target graduation window for the program. The company expects 90%+ degradation in Phase 1 for KT-579, aligning with dupilumab’s revenue share across its first four or five approved indications, and 80%+ inhibition of downstream cytokines. The IRF5 program could contribute significantly to Kymera’s revenue, with top indications like atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), and COPD expected to account for 95%+ of projected earnings.
In its BREATH Phase 2b study for type 2 asthma, Kymera is evaluating KT-621 in patients with high eosinophils and elevated fractional exhaled nitric oxide (FeNO). The primary efficacy readout will be the change in delta FEV1 at 12 weeks. The company did not design the BROADEN2 or BREATH studies to demonstrate dose-response but rather to select the optimal Phase 3 candidate. Terence Rooney, Chief Medical Officer, emphasized that while KT-621’s pathway blockade is scientifically comparable to dupilumab, it may not require identical efficacy thresholds.
Kymera’s updated timelines reflect confidence in its pipeline. Phase III regulatory discussions and further indications are targeted for 2027, with mid-2027 as the initial window for initiating Phase III studies, contingent on the BROADEN2 readout. The company’s focus remains on delivering oral therapies that address unmet needs in inflammatory diseases, positioning it to compete with established biologics while expanding its commercial footprint.
